Thanks for your comments. I couldn't agree more that there is a flip side to this issue. To promote drugs that have undesirable adverse effects (ie SFUs, glitazones) when there are agents available that not only do not have those ADRs, have outcome data - live longer, prevent renal disease etc- it is not appropriate for decisions to be made on cost only. Cost in the moment. Not the long term cost of treating or preventing complications. Keep up the good work. JG
Thanks for your comments. I couldn't agree more that there is a flip side to this issue. To promote drugs that have undesirable adverse effects (ie SFUs, glitazones) when there are agents available that not only do not have those ADRs, have outcome data - live longer, prevent renal disease etc- it is not appropriate for decisions to be made on cost only. Cost in the moment. Not the long term cost of treating or preventing complications. Keep up the good work. JG